Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

This study has been terminated.
(protocol violation)
Information provided by:
Sanofi Identifier:
First received: October 28, 2008
Last updated: September 14, 2009
Last verified: September 2009


  • To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline.


  • To assess the safety and tolerability of oxaliplatin
  • To assess time to progression and overall survival.

Condition Intervention Phase
Uterine Neoplasms
Drug: Oxaliplatin
Drug: 5-FluoroUracil
Drug: Folinic acid
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or Metastatic Cervical Cancer.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Response rate [ Time Frame: Throughout the study period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: Throughout the study period ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Throughout the study period ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: Throughout the study period ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: January 2003
Primary Completion Date: August 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
Drug: Oxaliplatin
85 mg/m²
Drug: 5-FluoroUracil
2,000 mg/m²
Drug: Folinic acid
20 mg/m²


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have Locally advanced/metastatic squamous or adenocarcinoma of the cervix
  • Prior therapy with cisplatin allowed
  • First-line treatment may have been surgery,radiotherapy or chemotherapy either as a single agent or multi-modality therapy
  • Must have measurable disease
  • Histologically Proven Carcinoma of the cervix
  • ECOG PS ≤2
  • No other serious concomitant illness
  • Fully recovered from any prior therapy
  • Lab: ANC >1500 mm³, Platelets > 100000 mm³, Creatinine ≤ 1.5 x Normal value, Bilirubin ≤ 1.5 x Normal value, SGPT (ALT) ≤ 2.5 x Normal value

Exclusion Criteria:

  • Known allergy to one of the study drugs
  • Peripheral neuropathy > grade2

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00782041

Sanofi aventis administrative office
Bangkok, Thailand
Sponsors and Collaborators
Study Director: Paibulsirijit Sompob, MD Sanofi
  More Information

No publications provided

Responsible Party: Medical Affairs Study Director, Sanofi-aventis Identifier: NCT00782041     History of Changes
Other Study ID Numbers: L_8311
Study First Received: October 28, 2008
Last Updated: September 14, 2009
Health Authority: Thailand: Food and Drug Administration

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Site
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Folic Acid
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Substances
Hematologic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Vitamin B Complex
Vitamins processed this record on November 27, 2015